Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-06 · accession 0001415889-25-001053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-07 | 2025-01-06 | SPRY | Shawver Laura | Dir | M - OptEx | $3.15 | +50.0K | 260.3K | +24% | +$157.5K |
| D | 2025-01-07 | 2025-01-06 | SPRY | Shawver Laura | Dir | S - Sale+OE | $11.10 | -50.0K | 210.3K | -19% | -$555.0K |
| D | 2025-01-07 | 2025-01-06 | SPRY | Shawver Laura | Dir | M - OptEx | $0.00 | -50.0K | 9,064 | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | M | A | 50,000 | $3.15 | 260,346 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-06 | S | D | 50,000 | $11.10 | 210,346 | D | — | — | (F2) The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-01-06 | M | D | 50,000 | $0.00 | 9,064 | D | $3.15 · — to 2032-05-01 | 50,000 Common Stock | (F3) Immediately exercisable. |